Talphera Inc
NASDAQ:TLPH

Watchlist Manager
Talphera Inc Logo
Talphera Inc
NASDAQ:TLPH
Watchlist
Price: 0.98 USD -1.26% Market Closed
Market Cap: 45.7m USD

Operating Margin

-46 539.3%
Current
Declining
by 28 768%
vs 3-y average of -17 771.3%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-46 539.3%
=
Operating Income
$-13m
/
Revenue
$28k

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-46 539.3%
=
Operating Income
$-13m
/
Revenue
$28k

Peer Comparison

Country Company Market Cap Operating
Margin
US
Talphera Inc
NASDAQ:TLPH
45.6m USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
982.2B USD
Loading...
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
Loading...
US
Johnson & Johnson
NYSE:JNJ
524.3B USD
Loading...
CH
Roche Holding AG
SIX:ROG
273.4B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
208.3B GBP
Loading...
CH
Novartis AG
SIX:NOVN
219B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
270.2B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
145.7B USD
Loading...
No Stocks Found

Market Distribution

Lower than 99% of companies in the United States of America
Percentile
1st
Based on 14 112 companies
1st percentile
-46 539.3%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Talphera Inc
Glance View

Market Cap
45.7m USD
Industry
Pharmaceuticals

AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. The company is headquartered in San Mateo, California and currently employs 19 full-time employees. The company went IPO on 2011-02-11. The firm is focused on the development and commercialization of therapies for use in medically supervised settings. The firm's nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the dialysis circuit during continuous renal replacement therapy (CRRT) for acute kidney injury (AKI) patients in the hospital, and for chronic kidney disease patients undergoing intermittent hemodialysis (IHD) in dialysis centers. LTX-608 is nafamostat formulation for direct intravenous (IV) infusion that shall be investigated and developed as a potential anti-viral for the treatment of COVID, acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), and acute pancreatitis. The firm is also engaged in developing two pre-filled syringes, namely Fedsyra and PFS-02.

TLPH Intrinsic Value
Not Available
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-46 539.3%
=
Operating Income
$-13m
/
Revenue
$28k
What is Talphera Inc's current Operating Margin?

The current Operating Margin for Talphera Inc is -46 539.3%, which is below its 3-year median of -17 771.3%.

How has Operating Margin changed over time?

Over the last 3 years, Talphera Inc’s Operating Margin has decreased from -1 789.8% to -46 539.3%. During this period, it reached a low of -51 614.8% on Mar 31, 2025 and a high of -1 789.8% on Dec 31, 2022.

Back to Top